This article is more than 5 years old. Information may no longer be current.
VIDEO: What GIs can learn about IMIDs from other specialists
Click Here to Manage Email Alerts
CHICAGO — In this exclusive video from the Interdisciplinary Autoimmune Summit, Stephen B. Hanauer, MD, medical director of the Digestive Health Center at Northwestern University Feinberg School of Medicine, discusses the importance of branching out and how medical conferences can help.
“It’s very important for us to listen to each other, to not be siloed into individual spaces,” Hanauer told Healio Gastroenterology and Liver Disease. “There’s so many similarities as far as the epidemiology and the therapeutic approaches. So, we need to learn from these similarities, as well as the differences.”
Hanauer said that immune mediated inflammatory diseases, such as inflammatory bowel disease or rheumatoid arthritis, are very heterogeneous and therefore, very complex. Researchers working across these diseases have difficulties establishing how to group patients or manage therapy through the use of biomarkers.
Learning from partners in the world of rheumatology and dermatology is also important because the diseases often come together, Hanauer said.
“Patients with inflammatory bowel disease that I see are more likely to have dermatologic manifestations or rheumatologic manifestations and vice versa for each of these diseases,” he said. “Coming together as immune-inflammatory specialists will help us to treat and actually personalize medicine for each of these disorders in the future.”
Disclosures: Hanauer reports financial ties to AbbVie, Actavis, Allergan, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Ferring, Genentech, Gilead, GSK, Hospira, Janssen, Eli Lilly, Merck, Nestle, Novartis, Pfizer, Prometheus, Receptos, Salix, Samsung Bioepis, Sanofi-Aventis, Seres Health, Shire, Takeda, Therakos, TiGenix, UCB and VHsquared
Click Here to Manage Email Alerts